Latham & Watkins represented Mineralys Therapeutics in the transaction.Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment…
Mineralys Therapeutics’ $118 Million Series B Financing
